Here we show that the long-acting GIP mono-agonist acyl-GIP reduced hyperlipidemia and atherosclerotic lesion formation in male LDLR-/- mice independently of body weight loss indicating an effect exclusively mediated by GIP signaling. This evidence concerns the gene LDLR and hyperlipidemia.